Obeticholic Acid—A Pharmacological and Clinical Review

Obeticholic Acid—A Pharmacological and Clinical Review

Obeticholic acid (OCA) or 6-alpha-ethyl-chenodeoxycholic acid is a semisynthetic modified bile acid derivative that acts on the farnesoid X receptor (FXR) as an agonist with a higher potency than bile acid. The FXR is a nuclear receptor highly expressed in the liver and small intestine and regulates...

Full description

Bibliographic Details
Main Authors:	Caezaan Keshvani, Jonathan Kopel, Hemant Goyal
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Future Pharmacology
Subjects:	obeticholic acid non-alcoholic fatty liver disease metabolic syndrome biliary cirrhosis primary biliary cholangitis non-alcoholic steatohepatitis
Online Access:	https://www.mdpi.com/2673-9879/3/1/17

Similar Items

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
by: Jhaveri MA, et al.
Published: (2017-08-01)

Obeticholic Acid for Primary Biliary Cholangitis
by: Annarosa Floreani, et al.
Published: (2022-10-01)

The Surging Function of Nanotechnology in the Management of Primary Biliary Cholangitis with Obeticholic Acid
by: Devyani Patil, et al.
Published: (2023-05-01)

Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment
by: Nicholas MacDonald, et al.
Published: (2024-01-01)

Update on Emerging Treatment Options for Primary Biliary Cholangitis
by: Aguilar MT, et al.
Published: (2020-05-01)

Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease
by: Seung Min Lee, et al.
Published: (2023-08-01)

Causal effects from inflammatory bowel disease on liver function and disease: a two-sample Mendelian randomization study
by: Yufeng Shu, et al.
Published: (2024-01-01)

Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomised controlled trial
by: Amardeep Khanna, et al.
Published: (2018-04-01)

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
by: Ludovico Abenavoli, et al.
Published: (2018-10-01)

Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China: A ten-year retrospective study
by: Ji Xiong, et al.
Published: (2015-08-01)

Toll-Like Receptors in Liver Fibrosis: cellular crosstalk and mechanisms
by: Ling eYang, et al.
Published: (2012-05-01)

Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity
by: Yuping Yang, et al.
Published: (2024-03-01)

The Role of Red Cell Distribution Width as a Prognostic Marker in Chronic Liver Disease: A Literature Review
by: Hunain Aslam, et al.
Published: (2023-02-01)

Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
by: Weiyi Qu, et al.
Published: (2021-10-01)

Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection
by: Bowlus CL
Published: (2016-09-01)

Primary biliary cholangitis
by: I. M. Iljinsky, et al.
Published: (2021-04-01)

Epidemiology of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A focused literature review
by: Yuichiro Eguchi, et al.
Published: (2020-10-01)

LIVER TRANSPLANTATION IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A MULTICENTRIC STUDY
by: Henrique de Aguiar Wiederkehr, et al.
Published: (2023-10-01)

Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis
by: Gregory Habig, et al.
Published: (2021-04-01)

The negative and detrimental effects of high fructose on the liver, with special reference to metabolic disorders
by: Mai BH, et al.
Published: (2019-05-01)

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
by: Cristina Piras, et al.
Published: (2021-10-01)

Expression of Integrin β1, Focal Adhesion Kinase, and PDZ-Binding Motif in Human Liver Cirrhosis and Simple Steatosis
by: Zahra Goli, et al.
Published: (2022-12-01)

Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease
by: Mira Thing, et al.
Published: (2024-01-01)

Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role
by: Stefania De Lorenzo, et al.
Published: (2020-10-01)

MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives
by: Mette Yde Hochreuter, et al.
Published: (2022-11-01)

Epidemiology and updated management for autoimmune liver disease
by: Nae-Yun Heo, et al.
Published: (2023-01-01)

Our Autoimmune Hepatitis Patients: Single Center Experience
by: Osman Özdoğan, et al.
Published: (2020-03-01)

Primary Sclerosing Cholangitis: A Clinical Update
by: Sridhar Sundaram, et al.
Published: (2019-09-01)

The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
by: Natasa Paklar, et al.
Published: (2023-11-01)

Primary sclerosing cholangitis and Biliary cirrhosis associated with Ulcerative colitis
by: Aleem Ahmed Khan, et al.
Published: (2011-07-01)

Current and future opportunities for the management of primary biliary cholangitis
by: Sandra Naffouj, et al.
Published: (2023-12-01)

URSODEZOKSIHOLEVAJA ACID: THERAPIST’S VIEW
by: V. M. Makhov, et al.
Published: (2017-11-01)

A case of metabolic syndrome, positive antinuclear antibodies and cirrhosis.
by: Alessandro Grasso
Published: (2007-09-01)

Ruptured hepatocellular carcinoma and non-alcoholic fatty liver disease, a potentially life-threatening complication in a population at increased risk
by: Carlos M. Nuño-Guzmán, et al.
Published: (2020-01-01)

Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma
by: Marco Castellana, et al.
Published: (2021-10-01)

Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease
by: Francesco Baratta, et al.
Published: (2015-07-01)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
by: Mohammad Alomari, et al.
Published: (2020-04-01)

Knowing what’s out there: awareness of Non Alcoholic Fatty Liver Disease.
by: Vishal eGhevariya, et al.
Published: (2014-03-01)

Systematic review and meta-analysis: Transient elastography compared to liver biopsy for staging of liver fibrosis in primary biliary cholangitis
by: Luis Antonio Manzo-Francisco, et al.
Published: (2023-07-01)

Diagnosis and Treatment of Primary Biliary Cholangitis
by: Kyung-Ah Kim
Published: (2023-02-01)